An anticonvulsive drug, valproic acid (valproate), has effects on the biosynthesis of fatty acids and polyketides in microorganisms

Prapassorn Poolchananu1,2, Panida Unagul1,4, Sanit Thongnest1, Suthep Wiyakrutta5, Nattaya Ngamrojanavanich6✉, Chulabhorn Mahidol1,7, Somsak Ruchirawat1,7,8 & Prasat Kittakoop1,7,8✉

Valproic acid or valproate (VPA) is an anticonvulsive drug used for treatments of epilepsy, bipolar disorder, and migraine headaches. VPA is also an epigenetic modulator, inhibiting histone deacetylase, and it has been subjected to clinical study for cancer treatment. During the investigation of VPA on a metabolite profile in a fungus, we found that VPA has significant effects on the production of some fatty acids. Further exploration of VPA on fatty acid profiles of microorganisms, fungi, yeast, and bacteria, as well as representative gut microbiome, revealed that VPA could enhance or reduce the production of some fatty acids. VPA was found to induce the production of trans-9-elaidic acid, a fatty acid that was previously reported to have cellular effects in human macrophages. VPA could also inhibit the production of some polyketides produced by a model fungus. The present work suggests that the induction or inhibition of fatty acid biosynthesis by VPA (100 µM) in gut microbiome could give effects to patients treated with VPA because high doses of VPA oral administration (up to 600 mg to 900 mg) are used by patients; the concentration of VPA in the human gut may reach a concentration of 100 µM, which may give effects to gut microorganisms.

Valproic acid (VPA) or valproate, an anticonvulsive drug, has been used as drug for the treatment of epilepsy, bipolar disorder, and for the prevention of migraine headaches. VPA has side effects, for example, hepatic steatogenesis in rats1, and negative influence on hepatic carbohydrate and lipid metabolism2. There were a number of fatal cases of hyperammonemia for patients treated with VPA1. In mitochondria, VPA undergoes fatty acid β-oxidation pathway, causing toxicity due to interference with mitochondrial β-oxidation, and many serious inborn errors of metabolism are caused by VPA treatment4. VPA interferes with carnitine palmitoyl-transferase I, a key enzyme in mitochondrial fatty acid β-oxidation, and thus inducing hepatotoxicity and weight gain for patients under VPA therapy5. VPA could inhibit N-acetyl glutamate synthetase, and thus inhibiting urea synthesis6,7. VPA was found to induce abnormal autism-like behaviors in mice8. Recently, a number of research groups paid attention on the risk of VPA on autism spectrum disorders9–14. The discovery that VPA is an inhibitor of histone deacetylase, a promising anticancer drug target, has stimulated the scientific community worldwide to investigate the detailed mechanisms of VPA in various aspects15,16. Recently, drug repurposing of VPA has been intensively explored for the treatment of various diseases, for example, the treatment of breast cancer17, colon cancer associated with diabetes mellitus18, diffuse intrinsic pontine glioma19, high-fat diet-induced hypertension20,
and HIV infection\textsuperscript{31}. VPA also inhibits MAP kinase signaling and cell cycle progression in the yeast model\textsuperscript{12} and sensitizes hepatocellular carcinoma cells to proton therapy through the suppression of NRF2 activation\textsuperscript{23}. VPA in combination with other anticancer drugs has been subjected to Phase II clinical study for cancer therapy\textsuperscript{24}. Gut microbiome plays important role for human health and diseases, and it has gradually received attention over the past 15 years\textsuperscript{25,26}. Many studies have revealed the functional interactions between the host (human) and gut microbiome, as well as the functions of gut microbiome in the healthy state and in certain disease states, e.g., diabetes, obesity, cancer, and liver diseases\textsuperscript{25}. Drug-microbiome interactions have recently received attention from the scientific community. Previous works demonstrated the drug interaction with human gut microbiome, for example, atypical antipsychotic drug interacting with the gut microbiome in a bipolar disease cohort\textsuperscript{27}. Herein we investigate the effect of VPA (100 µM) on fatty acid profile of fungi. It is known that epigenetic modulators, i.e., DNA methyltransferase and histone deacetylase inhibitors, could alter the biosynthesis of fungal metabolites, and thus changing natural product profiles with enhanced chemical diversity\textsuperscript{28}. Many studies revealed the effectiveness of epigenetic modifiers for the production of new secondary metabolites\textsuperscript{35} and enhance antimicrobial activity of fungal extracts\textsuperscript{36,37}. Initially, we preliminarily

### Table 1. Effect of VPA (100 µM) on fatty acid profile of the fungus Trichoderma reesi. \( p \leq 0.01 \) was selected as the minimum criterion for significance. \( p \leq 0.05 \) was selected as the minimum criterion for significance.

| Fungi, condition | C16:0 | C16:1 | C18:0 | C18:1 | C18:2 | C18:3 | C20:0 | C22:0 | C22:1 | C24:0 | Total fatty acid (%) |
|-----------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|---------------------|
| Fusarium oxysporum, control (without VPA) | 29.40 ± 4.91\textsuperscript{a} | 0.71 ± 0.06\textsuperscript{a} | 15.09 ± 3.82 \textsuperscript{a} | 32.93 ± 4.39 \textsuperscript{a} | 19.94 ± 3.45 \textsuperscript{a} | 0.44 ± 0.05 \textsuperscript{a} | 0.65 ± 0.18 \textsuperscript{a} | 0.43 ± 0.11 \textsuperscript{a} | 0.09 ± 0.02 \textsuperscript{a} | 0.33 ± 0.10 \textsuperscript{a} | 45.33 ± 4.84\textsuperscript{a} |
| F. oxysporum, 100 µM of VPA | 51.79 ± 5.14 \textsuperscript{b} | 0.00 \textsuperscript{b} | 20.29 ± 3.29 \textsuperscript{b} | 20.24 ± 2.17 \textsuperscript{b} | 5.27 ± 0.60 \textsuperscript{b} | 0.00 \textsuperscript{b} | 0.00 \textsuperscript{b} | 0.97 ± 0.09 \textsuperscript{b} | 1.44 ± 0.07 \textsuperscript{b} | 0.00 \textsuperscript{b} | 9.85 ± 2.53\textsuperscript{b} |
| Aspergillus aculeatus, control (without VPA) | 41.52 ± 1.61 \textsuperscript{a} | 0.28 ± 0.03 \textsuperscript{a} | 17.29 ± 2.11 \textsuperscript{a} | 29.46 ± 3.93 \textsuperscript{a} | 2.80 ± 0.13 \textsuperscript{a} | 0.00 \textsuperscript{a} | 0.84 ± 0.13 \textsuperscript{a} | 0.93 ± 0.08 \textsuperscript{a} | 0.00 | 6.88 ± 0.54 \textsuperscript{a} | 12.73 ± 1.56\textsuperscript{a} |
| A. aculeatus, 100 µM of VPA | 22.01 ± 1.85 \textsuperscript{b} | 0.14 ± 0.04 \textsuperscript{b} | 8.81 ± 1.16 \textsuperscript{b} | 27.83 ± 5.33 \textsuperscript{b} | 27.20 ± 4.36 \textsuperscript{b} | 1.27 ± 0.10 \textsuperscript{b} | 0.24 ± 0.01 \textsuperscript{b} | 1.20 ± 0.08 \textsuperscript{b} | 0.00 | 11.30 ± 1.55 \textsuperscript{b} | 29.13 ± 2.49\textsuperscript{b} |
| Xylaria globosa, control (without VPA) | 20.98 ± 1.83 \textsuperscript{b} | 0.00 | 21.57 ± 2.88 \textsuperscript{b} | 33.77 ± 1.61 \textsuperscript{b} | 21.31 ± 3.46 \textsuperscript{b} | 0.00 | 0.39 ± 0.05 \textsuperscript{b} | 0.00 | 0.00 | 0.00 | 1.98 ± 0.14 \textsuperscript{b} | 47.08 ± 6.00\textsuperscript{b} |
| X. globosa, 100 µM of VPA | 20.82 ± 4.50 \textsuperscript{b} | 0.00 | 22.36 ± 2.29 \textsuperscript{b} | 30.2 ± 1.37 \textsuperscript{b} | 24.08 ± 3.41 \textsuperscript{b} | 0.00 | 0.00 \textsuperscript{b} | 0.00 | 0.00 | 0.00 | 2.55 ± 0.13 \textsuperscript{b} | 48.67 ± 8.71\textsuperscript{b} |
| Cordyceps militaris, control (without VPA) | 36.38 ± 3.27 \textsuperscript{b} | 0.54 ± 0.08 \textsuperscript{b} | 7.84 ± 0.63 \textsuperscript{b} | 36.94 ± 1.42 \textsuperscript{b} | 18.03 ± 2.60 \textsuperscript{b} | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 61.55 ± 2.23\textsuperscript{b} |
| C. militaris, 100 µM of VPA | 31.85 ± 4.45 \textsuperscript{b} | 0.74 ± 0.09 \textsuperscript{b} | 6.56 ± 1.03 \textsuperscript{b} | 41.97 ± 2.45 \textsuperscript{b} | 18.88 ± 2.81 \textsuperscript{b} | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 58.45 ± 0.57\textsuperscript{b} |
| Aureobasidium pullulans, control (without VPA) | 29.6 ± 2.01 \textsuperscript{b} | 0.70 ± 0.05 \textsuperscript{b} | 9.05 ± 0.67 \textsuperscript{b} | 41.14 ± 1.17 \textsuperscript{b} | 17.36 ± 1.39 \textsuperscript{b} | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.5 ± 0.11 | 27.62 ± 3.65\textsuperscript{b} |
| A. pullulans, 100 µM of VPA | 29.08 ± 0.70 \textsuperscript{b} | 0.52 ± 0.05 \textsuperscript{b} | 11.94 ± 0.79 \textsuperscript{b} | 41.29 ± 0.52 | 15.08 ± 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.8 ± 0.24 | 40.16 ± 5.01\textsuperscript{b} |

### Table 2. Effect of VPA (100 µM) on fatty acid profile of fungi. \( p \leq 0.01 \) was selected as the minimum criterion for significance (for the same fatty acid and the same fungus with or without VPA). \( p \leq 0.05 \) was selected as the minimum criterion for significance (for the same fatty acid and the same fungus with or without VPA).

Results

Effects of VPA on a fatty acid profile of microorganisms. It is known that epigenetic modulators, i.e., DNA methyltransferase and histone deacetylase inhibitors, could alter the biosynthesis of fungal metabolites, and thus changing natural product profiles with enhanced chemical diversity\textsuperscript{28}. Many studies revealed the effectiveness of epigenetic modifiers for the production of new secondary metabolites in microorganisms, for example, proteasome-inhibitor\textsuperscript{29,30} and histone deacetylase inhibitor;\textsuperscript{31–33} this technique is collectively known as “One strain many compound” (OSMAC) approach. Previously, VPA, an inhibitor of histone deacetylase, was found to enhance tenfold-production of a fungal alkaloid\textsuperscript{34}, fumiquinazoline C, and could change the profile of secondary metabolites\textsuperscript{35} and enhance antimicrobial activity of fungal extracts\textsuperscript{36,37}. Initially, we preliminarily
investigated the effect of VPA on the metabolite production of the marine fungus *Trichoderma reesei*, which normally produces only mevalonolactone as a secondary metabolite (1H and 13C NMR spectra of mevalonolactone are in Supplementary Information). The aim of this work is to use VPA, an epigenetic modulator, to enhance the common biosynthetic pathway of terpenes and steroids. Previous works used different concentrations of VPA, e.g., 50µM, 60µM, 100µM, and 500µM, for the studies of the influence of VPA on the metabolite profile34–37. In the present work, we initially fed VPA with the concentrations of 100µM and 300µM to a culture of the marine fungus *Trichoderma reesei*, however, we found that VPA with the concentration at 300µM or higher than 300µM could inhibit the growth of the fungus. Therefore, we performed the experiment at the concentration of 100µM. The present work revealed that VPA did not induce the fungus *Trichoderma reesei* to produce new terpenes and steroids, but it showed the effects on fatty acid profiles as observed from 1H NMR spectrum of a crude cell extract. Detailed analysis by gas chromatography (GC) revealed that VPA significantly induced the production of palmitic acid (C16:0) from 9.39% in a control (without VPA) to 19.89% (2.11 times increase) in the fungus treated with VPA, while it reduced the production of oleic acid (C18:1) from 71.51% in a control to 57.19% (1.25 times decrease) (Table 1). The amounts of palmitoleic acid (C16:1), stearic acid (C18:0), linoleic acid (C18:2), and α-linolenic acid (C18:3) of a control were relatively the same as that in the VPA treated fungus. The fungus treated with VPA (49.99%) had the total fatty acid less than a control (65.26%) (Table 1).

As mentioned above, undesirable side effects related to fatty acid metabolism were observed in patients after treatment of VPA, for example, the influence on lipid metabolism2. VPA interfered with mitochondrial β-oxidation via fatty acid β-oxidation pathway, and thus causing serious inborn errors of metabolism after VPA treatment4. VPA induced hepatotoxicity and weight gain for patients because of the interference on a key enzyme

### Table 3. Effect of VPA (100µM) on fatty acid profile of yeast. *p ≤ 0.01 was selected as the minimum criterion for significance (for the same fatty acid and the same yeast with or without VPA). 1p ≤ 0.05 was selected as the minimum criterion for significance (for the same fatty acid and the same yeast with or without VPA).*

| Yeast, condition | C16:0 | C16:1 | C18:0 | C18:1 | C18:2 | C18:3 | Total fatty acid (%) |
|-----------------|-------|-------|-------|-------|-------|-------|---------------------|
| *Saccharomyces cerevisiae*, control (without VPA) | 15.25 ± 2.81 | 27.98 ± 2.17 | 7.52 ± 1.26 | 39.31 ± 2.11 | 7.96 ± 2.73 | 1.97 ± 0.21 | 39.68 ± 6.09 |
| *S. cerevisiae*, 100µM of VPA | 14.80 ± 1.54 | 30.42 ± 4.63 | 6.37 ± 1.38 | 41.13 ± 2.75 | 7.28 ± 1.83 | 0.00 | 41.39 ± 8.34 |
| Candida utilis, control (without VPA) | 29.03 ± 3.40 | 0.35 ± 0.09 | 6.60 ± 1.17 | 46.89 ± 4.82 | 15.86 ± 1.50 | 1.28 ± 0.08 | 24.35 ± 2.29 |
| C. utilis, 100µM of VPA | 47.16 ± 4.31 | 0.00 | 10.91 ± 1.85 | 34.21 ± 2.92 | 7.72 ± 0.36 | 0.00 | 15.62 ± 1.84 |
| Lachancea thermotolerans, control (without VPA) | 22.04 ± 2.89 | 25.52 ± 3.07 | 7.53 ± 1.52 | 15.65 ± 0.84 | 27.30 ± 1.73 | 1.97 ± 0.25 | 39.22 ± 6.39 |
| L. thermotolerans, 100µM of VPA | 22.10 ± 2.78 | 24.63 ± 0.70 | 7.35 ± 0.98 | 19.64 ± 0.71 | 24.65 ± 3.22 | 1.64 ± 0.19 | 39.29 ± 2.88 |

### Table 4. Effect of VPA (100µM) on fatty acid profile of bacteria. *p ≤ 0.01 was selected as the minimum criterion for significance.*

| Bacteria, condition | Fatty acid content (%), mean ± s.d. (n = 3) | C16:0 | C16:1 | C18:0 | C18:1 | C18:2 | C20:0 | C24:0 | Total fatty acid (%) |
|---------------------|------------------------------------------|-------|-------|-------|-------|-------|-------|-------|---------------------|
| Pedicoccus acidilactici, control (without VPA) | 52.02 ± 4.34 | 0.00 | 39.44 ± 4.04 | 0.00 | 7.00 ± 0.44 | 0.00 | 1.53 ± 0.06 | 7.92 ± 0.48 |
| P. acidilactici, 100µM of VPA | 48.52 ± 1.90 | 0.00 | 40.60 ± 3.14 | 0.00 | 10.87 ± 1.27 | 0.00 | 0.00 | 3.24 ± 0.10 |
| Bacillus amyloliquefaciens, control (without VPA) | 49.96 ± 1.35 | 9.72 ± 1.14 | 30.20 ± 5.63 | 0.00 | 10.12 ± 1.49 | 0.00 | 0.00 | 5.09 ± 1.06 |
| B. amyloliquefaciens, 100µM of VPA | 49.18 ± 1.14 | 4.41 ± 0.40 | 34.12 ± 4.19 | 0.00 | 12.29 ± 2.16 | 0.00 | 0.00 | 3.35 ± 0.76 |
| Acetobacter cerevisiae, control (without VPA) | 56.17 ± 6.30 | 0.00 | 37.02 ± 6.66 | 0.61 ± 0.05 | 5.76 ± 1.08 | 0.43 ± 0.07 | 0.00 | 8.59 ± 2.79 |
| A. cerevisiae, 100µM of VPA | 60.34 ± 0.65 | 0.00 | 33.27 ± 1.65 | 0.00 | 6.39 ± 1.55 | 0.00 | 0.00 | 5.50 ± 0.89 |
In contrast, VPA reduced the production of linoleic acid (C18:2) from 19.94% in control to 5.27% in the VPA (2.25 times of the control), and erucic acid (C22:1) (from 0.09% (control) to 1.44%, 16.0 times of the control). Fatty acid content (%), mean ± s.d. (n = 3)

| Fungi condition | C16:0 | C18:0 | C18:1 | C18:2 | C18:3 | C20:0 | C21:0 | C22:0 | C24:0 | Total fatty acid (%) |
|----------------|------|------|------|------|------|------|------|------|------|----------------------|
| Penicillium shearii, control (without VPA) | 24.29 ± 0.73 | 17.09 ± 2.94 | 39.94 ± 4.29 | 12.46 ± 1.43 | 0 | 1.65 ± 0.10 | 1.61 ± 0.19 | 1.30 ± 0.18 | 1.66 ± 0.37 | 49.13 ± 3.14 |
| Penicillium shearii, 100 µM of VPA | 16.86 ± 0.79 | 13.37 ± 1.98 | 42.23 ± 3.62 | 23.60 ± 3.49 | 0 | 1.08 ± 0.05 | 1.02 ± 0.14 | 0.67 ± 0.16 | 1.17 ± 0.13 | 54.31 ± 1.60 |
| Phialoconium sp., control (without VPA) | 28.73 ± 0.36 | 8.23 ± 0.43 | 43.27 ± 0.92 | 14.85 ± 0.56 | 2.53 ± 0.05 | 0.36 ± 0.02 | 0.58 ± 0.09 | 0.84 ± 0.08 | 0.61 ± 0.06 | 64.44 ± 5.15 |
| Phialoconium sp., 100 µM of VPA | 22.16 ± 0.38 | 7.94 ± 0.24 | 57.95 ± 0.48 | 7.47 ± 0.29 | 1.52 ± 0.06 | 0.58 ± 0.02 | 0.51 ± 0.09 | 1.05 ± 0.01 | 0.83 ± 0.03 | 72.17 ± 3.64 |
| Cladosporium sp., control (without VPA) | 35.29 ± 1.97 | 17.62 ± 1.74 | 32.69 ± 1.57 | 12.55 ± 2.13 | 0.20 ± 0.05 | 0.52 ± 0.02 | 0.44 ± 0.14 | 0.35 ± 0.03 | 0.34 ± 0.06 | 73.50 ± 3.86 |
| Cladosporium sp., 100 µM of VPA | 38.77 ± 2.50 | 9.90 ± 0.81 | 33.78 ± 2.30 | 15.20 ± 1.79 | 0.10 ± 0.02 | 0.80 ± 0.07 | 0.77 ± 0.11 | 0.53 ± 0.03 | 0.16 ± 0.07 | 58.34 ± 1.27 |
| Aspergillus flavipes, control (without VPA) | 21.30 ± 0.69 | 8.70 ± 0.46 | 42.17 ± 1.78 | 26.58 ± 1.10 | 0 | 0.24 ± 0.03 | 0.49 ± 0.02 | 0.24 ± 0.02 | 0.29 ± 0.05 | 72.03 ± 5.77 |
| Aspergillus flavipes, 100 µM of VPA | 18.34 ± 0.59 | 16.09 ± 1.74 | 39.13 ± 3.33 | 20.85 ± 1.76 | 0 | 1.77 ± 0.05 | 0.53 ± 0.03 | 2.10 ± 0.06 | 1.19 ± 0.07 | 74.77 ± 6.00 |

Table 5. Effect of VPA (100 µM) on fatty acid profile of representative gut fungi. *p ≤ 0.01 was selected as the minimum criterion for significance (for the same fatty acid and the same fungus with or without VPA). †p ≤ 0.05 was selected as the minimum criterion for significance (for the same fatty acid and the same fungus with or without VPA).

For fatty acid β-oxidation⁵. The interferences of VPA on fatty acid metabolism in patients and our preliminary data of VPA on the fatty profile of the fungus Trichoderma reesei (Table 1) prompted us to investigate the effects of VPA on fatty acid profile in other microorganisms including representative gut microbiome.

Microorganisms from the culture collection of Thailand Bioresource Research Center (TBRC), Thailand, are used for this work. The first group of microorganism is fungi including Fusarium oxysporum TBRC4265, Aspergillus aculeatus TBRC2535, Xylaria globosa TBRC6767, Cordyceps militaris TBRC6930, and Aureobasidium pullulans TBRC4786. These fungi represent five groups; the fungus F. oxysporum TBRC4265 and Aspergillus aculeatus TBRC2535 are marine and soil fungi, respectively, while X. globosa TBRC6767, C. militaris TBRC6930, and Aureobasidium pullulans TBRC4786 are endophyte, entomopathogenic (insect) fungus, and epiphyte or endophyte of plants, respectively. Each fungus was grown in potato dextrose broth under shaking condition in the presence (100 µM) or absence (control) of VPA, and fatty acid profiles of individual culture are in Table 2. The marine fungus F. oxysporum TBRC4265 produced ten fatty acids including palmitic acid (C16:0; 29.40%), palmitoleic acid (C16:1; 0.71%), stearic acid (C18:0; 15.09%), oleic acid (C18:1; 32.93%), linoleic acid (C18:2; 19.94%), α-linolenic acid (C18:3; 0.44%), arachidic acid (C20:0; 0.65%), docosanoic acid (C22:0; 0.43%), erucic acid (C22:1; 0.09%), and lignoceric acid (C24:0; 0.33%). After feeding 100 µM of VPA to the culture of the marine fungus F. oxysporum TBRC4265, the fungus completely stopped the production of palmitoleic acid (C16:1), α-linolenic acid (C18:3), arachidic acid (C20:0), and lignoceric acid (C24:0) (Table 2). However, VPA significantly enhanced the production of some fatty acids by the marine fungus F. oxysporum, e.g., palmitic acid (C16:0) from 29.4% (control) to 51.79%, 1.76 times of the control, docosanoic acid (C22:0) from 0.43% (control) to 0.97%, 2.25 times of the control, and erucic acid (C22:1) from 0.09% (control) to 1.44%, 16.0 times of the control. In contrast, VPA reduced the production of linoleic acid (C18:2) from 19.94% in control to 5.27% in the VPA treated culture of F. oxysporum, accounting for 3.78 times less than control (Table 2). The soil fungus Aspergillus aculeatus TBRC2535 did not produce α-linolenic acid (C18:3), however, after feeding 100 µM of VPA, the fungus was induced to produce α-linolenic acid 1.27% (Table 2). VPA enhanced the production of certain fatty acids by Aspergillus aculeatus TBRC2535, e.g., linoleic acid (C18:2) increased from 2.80% (control) to 27.20%, 9.71 times of the control and lignoceric acid (C24:0) increased from 6.88% (control) to 11.30%, 1.64 times of the control. However, the reduction of palmitic acid (C16:0) from 41.52% (control) to 22.01% (1.88 times less than the control), palmitoleic acid (C16:1) from 0.28% (control) to 0.14% (2.00 times less than the control), stearic acid (C18:0) from 17.29% (control) to 51.79%, 1.76 times of the control, and arachidic acid (C20:0) from 0.84% (control) to 0.24% (3.5 times less than the control) was observed in the VPA treated culture of Aspergillus aculeatus (Table 2). VPA was found to inhibit the production of arachidic acid (C20:0) in the endophytic fungus X. globosa TBRC6767, 0.39% of arachidic acid (C20:0) found in the control, but none found in the VPA treated culture (Table 2). VPA also inhibited the production of lignoceric acid (C24:0) in the insect fungus C. militaris TBRC6930, 0.28% of lignoceric acid produced in the control culture, but none detected in the VPA treated culture (Table 2). In contrast, VPA did not have significant effects on the fatty acid profile of the fungus Aureobasidium pullulans TBRC4786 (Table 2), which is an epiphyte or endophyte of plants. The total fatty acid of F. oxysporum was reduced from 45.33% to 9.85% (4.60 times less than the control), while those of Aspergillus aculeatus and Aureobasidium pullulans were increased from 12.73% to 29.13% (2.28 times more than the control) and from 27.62% to 40.16% (1.45 times more than the control) (Table 2). VPA did not give significant effects on the total.
Overall, these results indicated that VPA could stop or enhance the production of certain fatty acids in fungi, and it also had effects on the total fatty acid of some fungi.

Next, we tried to investigate the effects of VPA on the fatty acid profile of other microorganisms, e.g., yeast and bacteria (Tables 3 and 4). The yeasts, *Saccharomyces cerevisiae* TBRC1563, *Candida utilis* TBRC360, and *Lachancea thermotolerans* TBRC4347 were used as model microorganisms (Table 3); these strains are normally used in food and beverage production. The bacteria *Pediococcus acidilactici* TBRC7580, *Bacillus amyloliquefaciens* TBRC293, and *Acetobacter cerevisiae* TBRC6687, were used as model bacteria (Table 4). *P. acidilactici* and *A. cerevisiae* are normally used in fermented dairy products (e.g., yoghurt production) and meat (e.g., Thai fermented pork sausage or "Naem" in Thai), while *B. amyloliquefaciens* is a known source of α-amylase for the starch hydrolysis in food industry. As shown in Table 3, VPA completely stopped the production of α-linolenic acid (C18:3) in the yeasts, *S. cerevisiae* and *C. utilis*, and it also stopped the production of palmitoleic acid (C16:1) in *C. utilis*. Elevated levels of palmitic acid (C16:0) from 29.03% to 47.16% (increased by 1.62 times) and stearic acid (C18:0) from 6.60% to 10.91% (increased by 1.65 times) were observed in the VPA treated culture of *C. utilis*, while decreased level of linoleic acid (C18:2) from 15.86% to 7.72% (decreased by 2.05 times) was found in the VPA treated culture of *C. utilis* (Table 3). Moreover, the total fatty acid of the yeast, *C. utilis*, decreased from 24.35% to 15.62% (decreased by 1.55 times) was observed in the VPA treated culture of *C. utilis* (Table 3). In contrast, VPA did not have notable effects on the fatty acid profile and the total fatty acid, toward the yeast *C. utilis*. Interestingly, the yeast, *C. utilis*, was found as gut microbiome in pediatric patients with inflammatory bowel disease. The effects of VPA on fatty acid profile of bacteria are shown in Table 4;
VPA completely inhibited the production of lignoceric acid (C24:0) in the bacterium, *P. acidilactici*, and it also inhibited the production of oleic acid (C18:1) and arachidic acid (C20:0) in the bacterium, *A. cerevisiae*. Both *P. acidilactici* and *A. cerevisiae* are used in fermented dairy products and fermented meat (Thai sausage). The level of palmitoleic acid (C16:1) in the VPA treated culture of *B. amyloliquefaciens* was decreased from 9.72% to 4.41%, accounting for 2.2 times less than the control (Table 4).

Recently, gut microbiome has received attention worldwide. Therefore, we investigated the effects of VPA drug on fatty acid profile of certain representative gut microbiome, e.g., fungi and yeast. Representative gut fungi are *Penicillium shearii* TBRC2865, *Phialemonium* sp. TBRC4709, *Cladosporium* sp. TBRC4134, and *Aspergillus flavipes* BCC28681; the genera *Penicillium*, *Phialemonium*, *Cladosporium*, and *Aspergillus* are the most prevalent in human gut. VPA could enhance the production of linoleic acid (C18:2) from 12.46% (control) to 23.60% (increase 1.89 times) in the fungus *P. shearii* TBRC2865, however, it reduced the production of linoleic acid (C18:2) from 14.85% to 7.47% (1.98 times) in the fungus *Phialemonium* sp. (Table 5). VPA reduced the production of stearic acid (C18:0) from 17.62% (control) to 9.90% (1.77 times) in *Cladosporium* sp. TBRC4134, but it enhanced the production of stearic acid (C18:0) in *A. flavipes* BCC28681 from 8.70% (control) to 16.09% (1.85 times) (Table 5).

Other changes were the reduction of docosanoic acid (C22:0) in *P. shearii* TBRC2865 from 1.30% (control) to 0.67% (1.94 times); and increase of arachidic acid (C20:0) from 0.24% (control) to 1.77% (7.3 times), docosanoic acid (C22:0) from 0.24% (control) to 2.10% (8.75 times), and lignoceric acid (C24:0) from 0.29% (control) to 1.19% (4.1 times) in the fungus *A. flavipes* BCC28681 (Table 5). Three representative gut yeasts were *Candida catenulata* TBRC223, *Candida butyri* TBRC221 (syn. *Candida aaseri*), and *Saccharomyces ludwigii* TBRC2149; the genera *Candida* and *Saccharomyces* are commonly found as prevalent gut microbiome. In the present work, the yeast *S. cerevisiae* TBRC1563 previously mentioned above would be one of the representative gut yeasts (Table 3). We found that VPA completely inhibited the biosynthesis of α-linolenic acid (C18:3) in the yeast *S. cerevisiae* TBRC1563 (Table 3). The yeast *S. cerevisiae* TBRC1563 was found as gut microbiome in patients with inflammatory bowel disease. VPA completely stopped the production of palmitoleic acid (C16:1) and α-linolenic acid (C18:3) in *C. utilis* (Table 3). As shown in Table 6, VPA completely inhibited the biosynthesis of palmitoleic acid (C16:1) and α-linolenic acid (C18:3) in the yeast *Candida catenulata* TBRC223, while it induced the production of palmitoleic acid (C16:1) in *C. butyri* TBRC221 and *trans*-oleic acid or *trans*-9-elaidic acid (*trans*-C18:1) in *Saccharomyces ludwigii* TBRC2149. Normally, *trans*-9-elaidic acid is present in yeast and is degraded by peroxisomal multifunctional enzymes. It was found that *trans*-9-elaidic acid is less toxic than its *cis* isomer, oleic acid, and that they exhibited different effects in gene expression regulation and handling of excess fatty acids in yeast. Moreover, *trans*-9-elaidic acid could inhibit β-oxidation in human peripheral blood macrophages and increase intracellular...
and 5, and a polyketide 4 (Fig. 1). Compounds 2 and 3 were previously obtained as a mixture (1:1 ratio), which could not be separated by C18 reversed phase HPLC. In the present work, compounds 2 and 3 were obtained because of negative optical rotation, [α]_27.1. Since the above data demonstrated that VPA has effects on the production of fatty acid of gut bacteria, it is most likely that VPA may give effects on the biosynthesis of fatty acid of gut bacteria. The genus Pediococcus is found as intestinal flora of humans and animals, the bacterium Pediococcus acidilactici TBRC7580 mentioned in Table 4 may be used as the representative gut bacterium. Normally, P. acidilactici is used as probiotic, and oral feeding study revealed that this bacterium can survive in gastrointestinal tract of volunteers about two weeks after feeding. The present work showed that VPA completely inhibited the biosynthesis of lignoceric acid (C24:0) in P. acidilactici (Table 4).

It is known that the enzymes responsible for the biosynthesis of fatty acids and polyketide natural products share a great deal of similarities. Since the above data demonstrated that VPA has effects on the production of fatty acid, we envisage that VPA may have effects on the biosynthesis of polyketide natural products because fatty acid synthases and polyketide synthases have similar catalytic elements, for example, the use of common precursors and catalytic roles. Therefore, we investigated the effects of VPA on the production of polyketide natural products using the endophytic fungus Dothideomycete sp., which is a known source of polyketides in our laboratory. The fungus Dothideomycete sp. was previously found to produce a tricyclic polyketide, and other polyketides such as azaphilone, hybrid azaphilone-pyrene, calbistrin, and isochromanone, and it produced a large amount of austdiol (1) as the major azaphilone. However, in the present study, in addition to austdiol (1), the fungus Dothideomycete sp. produced other types of polyketide, i.e., known isobenzofuranone polyketides 2, 3, and 5, and a polyketide 4 (Fig. 1). Compounds 2 and 3 were previously obtained as a mixture (1:1 ratio), which could not be separated by C18 reversed phase HPLC. In the present work, compounds 2 and 3 were obtained after repeated HPLC separation; structures of both compounds were elucidated by analysis of 1D and 2D NMR spectra, as well as by data comparison with those published. The absolute configuration of isobenzofuranones (e.g., 2, 3, and 5) was established by the modified Mosher’s method and CD spectra after derivatization, as well as by X-ray analysis for quadricinctone A (5). The isomer with 3 R and 8 S (e.g., 2 and 5) had negative values, while that with 3 R and 8 R (e.g., 3) had positive values. Therefore, a polyketide 2 had 3 R and 8 S configuration because of negative optical rotation, [α]_27.1 = -38.1 (c = 0.22, CHCl3), while a polyketide 3 had 3 R and 8 R configuration with a positive optical rotation, [α]_27.1 = +38.9 (0.25, CHCl3). 1H and 13C NMR data and NMR spectra of 2 and 3 are in Supplementary Information. Compound 4 was a derivative of papparic acid, previously isolated from the fungus Ascochyta agropyri. The endophytic fungus Dothideomycete sp. was cultivated in 100 μM of VPA, and the comparison of the metabolite profile by HPLC analysis between the VPA treated culture and the control (without an addition of VPA) was investigated (Fig. 2). As shown in Fig. 2A, HPLC chromatogram of the control fungal culture showed peaks at retention time (t_R) of 6.5 min for austdiol (1), at t_R of 7.4 min for compounds 2 and 3, at t_R of 8.0 min for compound 4, and 10.2 min for quadricinctone A (5). HPLC chromatogram of VPA treated culture of the fungus Dothideomycete sp. is shown in Fig. 2B, showing a marked reduction (>90%) of the polyketide austdiol (1) and ca 50% reduction of quadricinctone A (5). However, the amounts of polyketides 2, 3, and 4 were not affected by VPA. This experiment demonstrated that VPA could affect the production of certain fungal polyketides.

Discussion

It is known that one of the side effects of VPA for patients is on lipid metabolism; VPA interferes with β-oxidation pathway of fatty acids, and thus causing toxicity. The negative impact of VPA treatment on serious inborn errors of metabolism is well documented. VPA induced hepatotoxicity and weight gain for patients because it interferes carnitine palmitoyl-transferase I, a key enzyme in fatty acid β-oxidation. The present work revealed that an anticonvulsant drug, VPA, has effects on the fatty acid profile of fungi, bacteria, and yeast, suggesting that this drug affects the biosynthesis of fatty acids in microorganisms. Normally, oral administration of VPA at doses of 10 to 15 mg/kg/day (i.e., 600 mg to 900 mg for the patient with 60 kg weight) is used for the treatment of epilepsy. However, doses of VPA for the prophylaxis of migraine headaches are 250–500 mg/day, while the treatment of manic episodes associated with bipolar disorder uses the dose up to 750 mg/day. In the present work, we found that VPA with the concentration 100 μM has effects on the biosynthesis of fatty acids in certain representative gut microbiome. It is possible that when patients taking high doses of VPA, i.e., 600 mg to 900 mg, the amount of VPA in patient gastrointestinal tract may reach at the concentration of 100 μM, which may affect the fatty acid biosynthesis in gut microbiome of patients. VPA induced abnormal autism-like behaviors in mice, and many studies showed the possible risk of VPA on autism spectrum disorders. The present work demonstrated that the biosynthesis of certain fatty acids was completely inhibited by VPA, while that of some fatty acids was induced by VPA. The present work showed that VPA could induce the production of trans-9-elastic acid in S. ludwigii TBRC2149 (Table 6); this is worth mentioning because trans-9-elastic acid was previously found to inhibit β-oxidation in human peripheral blood macrophages, and it could increase intracellular Zn²⁺ in human macrophages. Therefore, the induction or inhibition of certain fatty acids by VPA drug may have direct effects to patients treated with VPA. Fatty acid metabolism has a critical role in human since it sustains balanced homeostasis and the negative perturbations that would lead to disease development. The present work also demonstrated that VPA has effects on the biosynthesis of certain polyketide natural products produced by the fungus Dothideomycete sp.; this is because there are a great deal of similarities of the catalytic elements of fatty acid synthases and polyketide synthases. This knowledge may be applied for natural product research, aiming to diversify the polyketide structures.
In spite of the fact that VPA provides the effects on the biosynthesis of fatty acids in microorganisms such as fungi, yeast, and bacteria, the limitation of the present work is that representative gut microbiome used in this work does not well cover gut microbe community, particularly gut bacteria. We had selected certain genus of gut bacteria from the culture collection of Thailand Bioresource Research Center, however, most of them are anaerobic strains, growing under the conditions without oxygen. We tried to cultivate the selected gut bacteria representative using a homemade plastic incubator sealed with rubber, but failed to obtain cells for lipid extraction. In the present work, we could obtain cells from only one anaerobic bacterium, *Pediococcus acidilactici*, for lipid extraction; VPA was found to inhibit the production of lignoceric acid (C24:0) in the bacterium, *P. acidilactici* (Table 4). Recent study revealed that VPA and some psychotropic drugs gave effects on gut bacteria and short-chain fatty acids in rats, and VPA could decrease levels of propionate and butyrate, but enhancing the levels of isovalerate. Many psychotropic drugs have substantial effects of gut microbiome. The study in an animal model or a cohort study in patients that monitors the levels of fatty acids in feces and the composition of gut microbiota between the group treated with VPA and those without VPA will provide information regarding the precise effects of VPA on changes of fatty acids in gut microbiome.

Although this work employs the OSMAC approach using VPA as an epigenetic modulator to change the profile of secondary metabolites (natural products) in the fungus *Trichoderma reesei*, we propose that the effects of VPA toward the biosynthesis of fatty acids and polyketides may not through the epigenetic modulation. Previous works demonstrated that that VPA affected the fatty acid metabolism in patients, and interfered with β-oxidation via fatty acid β-oxidation pathway. Therefore, VPA may give direct effects toward fatty acids, i.e. the metabolism of fatty acids; however the epigenetic modulation on the biosynthesis of fatty acids could not be ruled out at this stage. Further study on the mechanistic insights into the cellular and molecular levels of VPA on changes of fatty acids and polyketides should be pursued.

**Methods**

**Cultivation of microorganisms.** Methods for cultivation of microorganisms, fungi, yeast, and bacteria are in Supplementary Information. Individual microorganisms were cultivated without an addition of VPA (control) or in the presence of VPA (100 μM). Cells of filamentous fungi were separated from broth by filtration using a filter paper, while cells of yeast and bacteria were collected by centrifuge at 8000 rpm. Cells of microorganisms were dried by freeze drying, and lipid in dried cells was extracted by hexane.

**Extraction of lipid and analysis of fatty acids.** Dried cells of microorganisms were extracted twice by maceration in hexane overnight at room temperature. Crude fat extract was individually transesterified with 4% sulphuric acid in methanol. A fat extract was dissolved in methanol containing 4% of sulphuric acid, and the mixture was heated at 90 °C for 1 h. Nonadecanoic acid (C19:0) was used as an internal standard. The esterified products were analyzed by a gas chromatography (GC) using a 30 m × 0.25 mm fused silica capillary column. The GC instrument was equipped with an automatic sampler and flame ionization detector (FID). The injector and detector temperatures were kept at 250 °C and 260 °C, respectively, and helium was used as a carrier gas at a linear velocity of 30 cm/s. The initial temperature for GC column at 200 °C was held for 10 min, and then increased at 20 °C/min to 230 °C, where it was held for 17 min. Individual fatty acid esters were identified based on the retention times relative to fatty acid methyl ester standards (Supelco 37 Component FAME Mix as the standard for methyl esters).

**Isolation of mevalonolactone.** A crude broth extract (198 mg) of the fungus *Trichoderma reesei* was separated by Sephadex LH-20 column chromatography (CC) (size 2 × 132 cm), eluted with methanol, yielding twelve fractions (F1-F12). A fraction F8 (79 mg) was further separated by Sephadex LH-20 CC (size 1.5 × 126 cm), eluted with methanol, to give nine fractions (F81-F89). A fraction F81 was purified by C18 reversed phase HPLC, and then separated by Sephadex LH-20 column chromatography (CC) (size 2 × 132 cm), eluted with a solvent system of MeOH:H2O (60:40), to give mevalonolactone (11.7 mg). 1H and 13C NMR spectra of mevalonolactone are in Supplementary Information.

**Isolation of compounds 1-5.** A crude broth extract (107.6 mg) of the fungus *Dothideomycete* sp. was separated by C18 reversed phase HPLC using MeOH:H2O (60:40) as a mobile phase to yield compounds 1 (9.2 mg), 4 (4.8 mg), and 5 (5.7 mg), respectively. However, compounds 2 and 3 were obtained as a mixture from the first HPLC separation. Effort to separate compounds 2 and 3 had been made by repeated HPLC separation using MeOH:H2O (40:60) as a mobile phase, yielding compounds 2 (12.8 mg) and 3 (7.1 mg).

**Structure elucidation of fungal metabolites by spectroscopic techniques.** 1H, 13C, and 2D NMR spectroscopic data were obtained from on 400 MHz NMR spectrometer (1H at 400 MHz, 13C at 100 MHz), or 600 MHz NMR spectrometer (1H at 600 MHz, 13C at 150 MHz). Deuterated CDCl3 was used as an NMR solvent. HRMS data were obtained from ESI-TOF mass spectrometer. Data for optical rotations for compounds 2 and 3 were obtained from a polarimeter.

**Statistical analysis method.** Statistical analysis of all data, three replications per each condition of an individual microorganism, was performed using the IBM SPSS Statistics 22 software, Independent-Samples T test method. Differences of fatty acid content between each group (control without VPA or with 100 μM of VPA) were determined by two-tailed t test, and data was reported as mean±s.d. with the significance set at p < 0.01 or at p < 0.05.

Received: 12 March 2020; Accepted: 18 May 2020;
Published online: 09 June 2020
References

1. Lewis, J. H., Zimmerman, H. J., Garrett, C. T. & Rosenberg, E. Valproate-induced hepatic steatogenesis in rats. *Hepatology* 2, 870–873 (1982).

2. Becker, C.-M. & Harris, R. A. Influence of valproic acid on hepatic carbohydrate and lipid metabolism. *Arch Biochem Biophys* 223, 381–392 (1983).

3. Verrotti, A., Trotta, D., Morgese, G. & Chiarelli, F. Valproate-induced hyperammonemic encephalopathy. *Metab Brain Dis* 17, 367–373 (2002).

4. Silva, M. F. et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. *J Inherit Metab Dis* 31, 205–216 (2008).

5. Aires, C. C. et al. Inhibition of hepatic carnitine palmityl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis. *Biochem Pharmacol* 79, 792–799 (2010).

6. Hjelm, M., Oberhofer, V., Seakins, J., Thomas, S. & Kay, J. D. Valproate inhibition of urea synthesis. *Lancet* 1, 923–924 (1987).

7. Hjelm, M., Oberhofer, V., Seakins, J., Thomas, S. & Kay, J. D. Valproate-induced inhibition of urea synthesis and hyperammonemia in healthy subjects. *Lancet* 2, 859 (1986).

8. Kataoka, S. et al. Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid. *Int. J. Neuropsychopharmacol* 16, 91–103 (2013).

9. Sgadò, P., Rosa-Salva, O., Versace, E. & Valtortigara, G. Embryonic exposure to valproic acid impairs social predispositions of newly-hatched chicks. *Sci Rep* 8, 5919 (2018).

10. Saier, L., Duclot, F., Wang, Z. & Kabbaj, M. Consequences of prenatal exposure to valproic acid in the socially monogamous prairie voles. *Sci Rep* 9, 2453 (2019).

11. Mahmood, U. et al. Dendritic spine anomalies and PTEN alterations in a mouse model of VPA-induced autism spectrum disorder. *Pharmacol Res.* 128, 110–121 (2018).

12. Nicolini, C. & Fahnstock, M. The valproic acid-induced rodent model of autism. *Exp Neurol* 299, 217–227 (2018).

13. Fontes-Dutra, M. et al. Abnormal preference-like pro-social behaviour in the valproic acid model of autism spectrum disorder. *Behav Brain Res.* 364, 11–18 (2019).

14. Hajasolmani, R. et al. Hyperexcitability of hippocampal CA1 pyramidal neurons in male offspring of a rat model of autism spectrum disorder (ASD) induced by prenatal exposure to valproic acid: A possible involvement of Ih channel current. *Brain Res.* 1708, 188–199 (2019).

15. Phiel, C. J. et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. *J. Biol. Chem.* 276, 36734–36741 (2001).

16. Gottlicher, M. et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. *EMBO J.* 20, 6969–6978 (2001).

17. Heers, H., Stanislav, J., Harrelson, J. & Lee, M. W. Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer. *Eur. J. Pharmacol.* 835, 61–74 (2018).

18. Patel, M. M. & Patel, B. M. Repurposing of sodium valproate in colon cancer associated with diabetes mellitus: Role of HDAC inhibition. *Eur. J. Pharm. Sci.* 121, 188–199 (2018).

19. Killick-Cole, C. L. et al. Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma. *Plos One* 12, e0176855 (2017).

20. Choi, J. et al. Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1/a angiotensin II axis. *Int. J. Obes.* 41, 1702–1709 (2017).

21. Crosby, B. & Deas, C. M. Repurposing medications for use in treating HIV infection: A focus on valproic acid as a latency-reversing agent. *J. Clin. Pharm. Ther.* 43, 740–745 (2018).

22. Desfossés-Baron, K. et al. Valproate inhibits MAP kinase signalling and cell cycle progression in *S. cerevisiae*. *Sci. Rep.* 6, 36013 (2016).

23. Yu, J. et al. Valproic acid sensitizes hepatocellular carcinoma cells to proton therapy by suppressing NRF2 activation. *Sci. Rep.* 7, 14986 (2017).

24. Caponigro, F. et al. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck: V-CHANCE trial. *RMC Cancer* 16, 918 (2016).

25. Shreiner, A. B., Kao, J. Y. & Young, V. B. The gut microbiome in health and in disease. *Gastroenterol Clin.* 47, 69–75 (2018).

26. Cani, P. D. Human gut microbiome: hopes, threats and promises. *Gut* 67, 1716–1725 (2018).

27. Flowers, S. A., Evans, S. J., Ward, K. M., McInnis, M. G. & Ellingrod, V. L. Interaction between atypical antipsychotics and the gut microbiome in a bipolar disease cohort. *Pharmacotherapy* 37, 261–267 (2017).

28. Williams, R. B., Henrikson, J. C., Hoover, A. B., Lee, A. E. & Cichewicz, R. H. Epigenetic remodeling of the fungal secondary metabolome. *Org. Biomol. Chem.* 6, 1895–1897 (2008).

29. VanderMolen, K. M. et al. Epigenetic manipulation of a filamentous fungus by the proteasome-inhibitor bortezomib induces the production of an additional secondary metabolite. *RSC Adv.* 4, 183329–183335 (2014).

30. Li, Y., Zhang, F., Banakar, S. & Li, Z. Bortezomib-induced new bergamotene derivatives xylariterpenoids H–K from sponge-derived fungus Pestalotiopsis maculans 16F-12. *RSC Adv.* 9, 599–608 (2019).

31. Gubiani, J. R. et al. An epigenetic modifier induces production of (10'S)-verruculide B, an inhibitor of protein tyrosine phosphatases by Phoma sp. nov. *LG0217*, a fungal endophyte of *Pestalotiopsis* sp. LG41 by a histone deacetylase inhibitor for production of decalin-containing compounds. *J. Nat. Prod.* 80, 983–988 (2017).

32. Del-Hawary SS et al. Epigenetic modifiers induce bioactive phenolic metabolites in the marine-derived fungus *Penicillium brevicompactum*. *Mar Drugs* 16 (2018).

33. Li, G. et al. Epigenetic modulation of endophytic *Epigenicillium* sp. LG41 by a histone deacetylase inhibitor for production of decalin-containing compounds. *J. Nat. Prod.* 80, 983–988 (2017).

34. Magotra, A. et al. Epigenetic modifier induced enhancement of fumiquinazoline C production in *Aspergillus fumigatus* (GA-L7): an endophytic fungus from *Grewia asiatica L.* *AMB Express* 7, 43 (2017).

35. Triastuti, A. et al. How histone deacetylase inhibitors alter the secondary metabolites of *Botryosphaeria mammame*, an endophytic fungus isolated from *Bixa orellana*. *Chem Biodivers* 16, e1800485 (2019).

36. Zuta, C. et al. Fungi treated with small chemicals exhibit increased antimicrobial activity against facultative bacterial and yeast pathogens. *BioMed. Res. Int.* 2014, 13 (2014).

37. Zuta, C. et al. Valproic acid induces antimicrobial compound production in *Doratomyces microspores*. *Front Microbiol* 7, 510 (2016).

38. Chehoud, C. et al. Fungal signature in the gut microbiota of pediatric patients with Inflammatory bowel disease. *Inflamm Bowel Dis* 21, 1948–1956 (2015).

39. Mar Rodriguez, M. et al. Obesity changes the human gut mycobiome. *Sci. Rep.* 5, 14600 (2015).

40. von Rosenvinge, E. C. et al. Immune status, antibiotic medication and pH are associated with changes in the stomach fluid microbiota. *ISME J.* 7, 1354–1366 (2013).

41. Gouba, N., Raoul, D. & Drancourt, M. Plant and fungal diversity in gut microbiota as revealed by molecular and culture investigations. *Plos One* 8, e59474 (2013).

42. Scanlan, P. D. & Marchesi, J. R. Micro-eukaryotic diversity of the human distal gut microbiota: qualitative assessment using culture-dependent and -independent analysis of feces. *ISME J.* 2, 1183–1193 (2008).
43. Hoffmann, C. et al. Archaea and fungi of the human gut microbiome: correlations with diet and bacterial residents. *Plos One* **8**, e66019 (2013).
44. Nash, A. K. et al. The gut mycobionte of the Human Microbiome Project healthy cohort. *Microbiome* **5**, 153 (2017).
45. Sokol, I., Gawel, A. & Bobrek, K. The prevalence of yeast and characteristics of the isolates from the digestive tract of clinically healthy turkeys. *Avian Dis* **62**, 286–290 (2018).
46. Lucena-Padros, H., Caballero-Guerrero, B., Maldonado-Barragan, A. & Ruiz-Barba, J. L. Microbial diversity and dynamics of Spanish-style green table-olive fermentations in large manufacturing companies through culture-dependent techniques. *Food Microbiol* **42**, 154–165 (2014).
47. Gurvitz, A., Hamilton, B., Ruis, H. & Hartig, A. Peroxidosomal degradation of trans-unsaturated fatty acids in the yeast *Saccharomyces cerevisiae*. *J. Biol. Chem.* **276**, 895–903 (2001).
48. Nakamura, T. et al. Trans 18-carbon monoenoic fatty acid has distinct effects from its isomeric cis fatty acid on lipotoxicity and gene expression in *Saccharomyces cerevisiae*. *J. Biosci. Bioeng.* **123**, 33–38 (2017).
49. Zacherl, J. R. et al. Elaidate, an 18-carbon trans-monoenoic fatty acid, inhibits β-oxidation in human peripheral blood macrophages. *J. Cell. Biochem.* **115**, 62–70 (2014).
50. Zacherl, J. R. et al. Elaidate, an 18-carbon trans-monoenoic fatty acid, but not physiological fatty acids increases intracellular Zn2++ in human macrophages. *J. Cell Biochem.* **116**, 524–532 (2015).
51. Vaughan, E. E., Heilig, H. G., Ben-Amor, K. & de Vos, W. M. Diversity, vitality and activities of intestinal lactic acid bacteria and bifidobacteria assessed by molecular approaches. *FEMS Microbiol. Rev.* **29**, 477–490 (2005).
52. Balgir, P. P., Kaur, B., Kaur, T., Daroch, N. & Kaur, G. In vitro and in vivo survival and colonic adhesion of *Pediococcus acidilactici* MTCC5101 in human gut. *Biomed. Res. Int.* **2013**, 583850 (2013).
53. Smith, S. & Tsai, S. C. The type I fatty acid and polyketide synthases: a tale of two megasynthases. *Special. Microbiol.* **10**, 202–208 (2003).
54. Senadeera, S. P., Wiyakrutta, S., Mahidol, C., Ruchirawat, S. & Kittakoop, P. A novel tricyclic polyketide and its biosynthetic precursor azaphilone derivatives from the endophytic fungus *Dothideomycete* sp. *Org. Biomol. Chem.* **10**, 7220–7226 (2012).
55. Hewage, R. T., Aree, T., Mahidol, C., Ruchirawat, S. & Kittakoop, P. One strain-many compounds (OSMAC) method for production of polyketides, azaphilones, and an isochromanone using the endophytic fungus *Dothideomycete* sp. *Phytochemistry* **108**, 87–94 (2014).
56. Wijesekara, K., Mahidol, C., Ruchirawat, S. & Kittakoop, P. Metabolite diversification by cultivation of the endophytic fungus *Dothideomycete* sp. in halogen containing media: Cultivation of terrestrial fungus in seawater. *Bioorg. Med. Chem.* **25**, 2868–2877 (2017).
57. Gerea, A. L. et al. Secondary metabolites produced by fungi derived from a microbial mat encountered in an iron-rich natural spring. *Tetrahedron Lett.* **53**, 4202–4205 (2012).
58. Tayone, W. C. et al. Stereochemoical investigations of isochromenones and isobenzofuranones isolated from *Leptosphaeria* sp. *KTC 727*. *J. Nat. Prod.* **74**, 425–429 (2011).
59. Prompanya C. et al. New polyketides and new benzoic acid derivatives from the marine sponge-associated fungus *Neosartorya quadricincta* KUFA 0081. *Mar. Drugs* **14** (2016).
60. Evidente, A. et al. Papyracillic acid, a phytotoxic 1,6-dioxaspiro[4,4]nonene produced by *Ascochyta agropyrina* Var. *nana*, a potential mycoherbicide for *Elytrigia repens* biocntrol. *J. Agric. Food Chem.* **57**, 11168–11173 (2009).
61. Suburu, J. et al. Fatty acid metabolism: Implications for diet, genetic variation, and disease. *Food Biosci.* **4**, 1–12 (2013).
62. Cussotto, S. et al. Differential effects of psychotropic drugs on microbiome composition and gastrointestinal function. *Psychopharmacology* **236**, 1671–1685 (2019).
63. Cussotto, S., Clarke, G., Dinan, T. G. & Cryan, J. F. Psychotropics and the microbiome: a chamber of secrets. *Psychopharmacology* **236**, 1411–1432 (2019).
64. Ungul, P. et al. Isolation, fatty acid profiles and cryopreservation of marine thraustochytrids from mangrove habitats in Thailand. *Botanica Marina* **60**, 363–379 (2017).

**Acknowledgements**

This work is supported by the Center of Excellence on Environmental Health and Toxicology, Science & Technology Postgraduate Education and Research Development Office (PERDO), Ministry of Education. P.P. thanks the 100th Anniversary Chulalongkorn University Fund for Doctoral Scholarship.

**Author contributions**

P.P.: Investigation, Formal analysis, Writing-original draft; P.U.: Investigation, Formal analysis; S.T.: Formal analysis; S.W.: Investigation; N.N.: Formal analysis; C.M.: Supervision; S.R.: Supervision, Funding acquisition; P.K.: Conceptualization, Writing-original draft, Writing-review & editing.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-66251-y.

Correspondence and requests for materials should be addressed to N.N. or P.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
